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Background: Small vessels have the pivotal role for the brain’s autoregulation. The
arteriosclerosis-dependent alteration of the brain perfusion is one of the major determinants
in small vessel disease. Endothelium distress can potentiate the flow dysregulation and lead
to subcortical vascular dementia (sVAD). sVAD increases morbidity and disability.
Epidemiological studies have shown that sVAD shares with cerebrovascular disease most
of the common risk factors. The molecular basis of this pathology remains controversial.
Purpose: To detect the possible mechanisms between small vessel disease and sVAD,
giving a broad vision on the topic, including pathological aspects, clinical and laboratory
findings, metabolic process and cholinergic dysfunction.
Methods: We searched MEDLINE using different search terms (“vascular dementia”,
“subcortical vascular dementia”, “small vessel disease”, “cholinergic afferents”, etc).
Publications were selected from the past 20 years. Searches were extended to Embase,
Cochrane Library, and LILIACS databases. All searches were done from January 1, 1998
up to January 31, 2018.
Results: A total of 560 studies showed up, and appropriate studies were included.
Associations between traditional vascular risk factors have been isolated. We remarked
that SVD and white matter abnormalities are seen frequently with aging and also that
vascular and endothelium changes are related with age; the changes can be accelerated by
different vascular risk factors. Vascular function changes can be heavily influenced by
genetic and epigenetic factors.
Conclusion: Small vessel disease and the related dementia are two pathologies that deserve
attention for their relevance and impact in clinical practice. Hypertension might be a
historical problem for SVD and SVAD, but low pressure might be even more dangerous;
CBF regional selective decrease seems to be a critical factor for small vessel disease-related
dementia. In those patients, endothelium damage is a super-imposed condition. Several
issues are still debatable, and more research is needed.
Keywords: subcortical vascular dementia, vascular damage, small vessel disease, brain’s
autoregulation
Introduction: traditional perspectives and recently
acquired information
Many authors have widely questioned vascular damage for its role in causing
dementia. Consensus criteria for the clinical diagnosis of the significant dementing
disorders have recently been updated, both for Alzheimer Disease (AD), Parkinson
disease dementia (PDD) and Lewy Body Disease (DBL), Frontotemporal Lobe
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Degeneration (FTLD).1–5 Previous diagnostic criteria for
vascular dementia (VaD) required the presence of memory
loss and the severity of cognitive impairment sufficient to
adversely affect independent functioning consistent with
dementia. Despite multiple attempts, no generally accepted
morphologic substrates have been included in the currently
used clinical diagnostic criteria for VaD.6,7
With time, different diagnostic guidelines for VaD have
been described. The commonly used are the National
Insititute of Neurological Disorders and Stroke Association
International pour la Recherche et l’Enseignement en
Neurosciences (NINDS-AIREN) guideline.8 For completion
of probable vascular Dementia, all should be present:
1. Dementia as impairment of memory and any other 2
or more cognitive domains, preferably established
by clinical examination and documented by the
neuropsychological test.
2. The presence of cerebrovascular diseases as the
presence of focal neurological signs and evidence
of the same in the brain imaging.
3. A relationship between dementia and cerebrovascu-
lar disease as one or both:
a. The onset of dementia within three months fol-
lowing a recognized stroke;
b. Abrupt deterioration on cognitive functions or fluc-
tuation, stepwise progression of cognitive deficits.
For subcortical ischemic vascular dementia, the brain ima-
ging would show either the Binswanger-type white matter
lesions or lacunar infarcts with the absence of cortical non-
lacunar territorial infarct and watershed infarcts, and other
causes of white matter lesions. The temporal relationship
may also be absent.8
The International Classification of disease, 10th revi-
sion (ICD-10) includes diagnostic features:
1. General criteria for dementia must be met;
2. Unequal distribution of deficits in higher cognitive
functions, with some affected and others, relatively
spared;
3. Focal brain damage as at least one of the following
(Unilateral spastic weakness of the limbs, unilater-
ally increased tendon reflexes, extensor plantar
response, pseudobulbar palsy);
4. Evidence from the history, examination or test of
significant cerebrovascular disease, etiologically
related to dementia.9
ICD-10 distinguished between:
● vascular dementia of acute onset: as it usually develops
within one month, but within no longer than three
months after a succession of strokes, rarely after a single
broad stroke;
● multi-infarct dementia: which onset is usually gra-
dual (within three to six months, following many
minor ischemic episodes).
● Subcortical vascular dementia: with a history of hyper-
tension and clinical examination, along with investiga-
tions showing vascular disease to be located in the deep
white matter of the cerebral hemispheres, with preserva-
tion of the cerebral cortex.9
A more complex pathological description (mainly dis-
cussed below) has been employed, extending the clinical
diagnosis to strategic infarct, hypoxic-ischemic dementia,
venous infarct dementia, and hemorrhagic dementia.10,11
Recently, the Diagnostic and Statistical Manual of
Mental disorders (5th Edition) redefined some aspects of
clinical classification, and all the dementias are called
Neurocognitive disorders.12 Here, the probable vascular
neurocognitive disorder is described by:
1. Criteria met for the major or mild neurocognitive
disorder.
2. Clinical features are consistent with a vascular
etiology, as either the following:
a. the onset of the cognitive deficits is temporally
related to one or more vascular events;
b. Evidence for a decline is prominent in elaborate
attention (including processing speed) and fron-
tal executive functions;
c. Evidence of the presence of cerebrovascular disease
from history, physical examination and neuroima-
ging, considering sufficient to account for neuro-
cognitive deficits.
Possible vascular neurocognitive disorders should be diag-
nosed as:
1. Clinical criteria supported by neuroimaging evi-
dence of significant parenchymal injury attributed
to the cerebrovascular disease.
2. The neurocognitive syndrome is temporally related
to one or more documented cerebrovascular events.
3. Both clinical and genetic evidence of cerebrovascu-
lar disease is present.13,14
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The most recent position summarizes the Standards for
reportingVascular changes on nEuroimaging (STRIVE) for a
recommended standard for research with MRI, but also with
CT,15 completed a structured process to develop a common
advisory about terms and definitions for features visible on
MRI and minimum standards for image acquisition. Signs of
small vessel disease include a conventional MRI recent sub-
cortical infarcts, white matter hyperintensities, lacunes, pro-
minent perivascular spaces, and cerebral microbleeds, with
possible consequent atrophy.
Vascular cognitive alterations are described as due to
vascular dementia (VaD).16
Other include vascular cognitive disorder (VCD),
while subcortical VAD (sVAD) has been employed to
define a circumscribed syndrome, related to small vessel
disease.17–21 Being so difficult to categorize the different
vascular subtypes of dementia, today it is widely accepted
to define the cognitive impairment related to vascular
dementia as Vascular Cognitive Impairment (VCI).22
VCI refers to a vast and almost comprehensive spec-
trum of vascular brain pathologies that contribute to cog-
nitive impairment, ranging from mild and subjective
cognitive decline to overt dementia.23
The difference between VaD subtypes may depend on
the anatomical distribution of the vascular insults. Usually,
small artery disease is more often associated with subcor-
tical VaD than with cortical and cortical-subcortical VaD.
Subcortical VaD is homogeneous, with the small-vessel
disease as the primary vascular etiology, lacunar infarcts,
and ischemic white matter lesions.24
Cerebral small vessel disease (SVD) is an umbrella
term covering a variety of abnormalities related to small
blood vessels in the brain. SVD results from damage to the
small penetrating arteries and arterioles in the brain, (9)
the prevalence of SVD increases exponentially with aging:
from approximately 6% to 7% at age 60 to 28% at age
80.25
Cerebral small vessel disease (SVD) is a common
cause of stroke, cognitive impairment, and gait distur-
bances, which slowly progress to vascular Parkinsonism
and dementia but can be differentiated from Alzheimer’s
disease considering neuroimaging findings (it is associated
with more extensive white matter lesions, less severe
hippocampal atrophy and the absence of cerebral amyloid
angiopathy).26,27
Substantial evidence shows that small vessel disease
shares many risk factors and prognostic impacts in specific
clinical settings.21 Moreover, inducing an increased blood
pressure and hyperglycemia, the presence of small vessel
disease confers a risk of hemorrhagic transformation in
brain ischemia in 10% of cases.28–33
In the clinical practice, small vessel disease is gener-
ally associated with the typical vascular “static” risk fac-
tors, such as hypertension, hyperlipidemia, diabetes,
obesity, atherosclerosis, atrial fibrillation, and insufficient
physical aerobic activity.34–43 Vascular Dementia increases
the morbidity, disability, and healthcare costs of the grow-
ing elderly population, decreasing their quality of life.44–46
Its prevention and treatment are critical research and clin-
ical priorities.
Neuropsychological pattern profiles of sVaD are distin-
guished by poor executive function, poor planning, working
memory alterations, loss of inhibition, reduced mental flex-
ibility, multitasking procedures invalidation, and decrease
speed of executive process.47 Neuroimaging standards
implement the clinical definition of subcortical vascular
dementia, which relies on cerebral small vessel disease.
Different studies have been realized with this aim.48
Our works purposes were to detect the possible
mechanisms between small vessel disease and sVaD, giv-
ing a broad vision on the topic, including pathological
aspects, clinical and laboratory finding, metabolic pro-
cesses and cholinergic dysfunction, pointing out the
dynamic process that links small vessel disease to subcor-
tical dementia, describing some crucial measures able to
delay or even interrupt this process.
Search strategy and selection criteria
We searched MEDLINE using the search terms “vascular
dementia,” “subcortical vascular dementia,” “vascular
cognitive impairment,” “small vessel disease,” “choliner-
gic afferents,” “arteriolosclerosis” “cerebral flow regula-
tion,” “neurovascular coupling,” “endothelium,” smooth
muscle cells arteries".
Publications were selected mostly form the past
20 years, but did not exclude frequently referenced and
highly regarded older publications. Researchers have been
extended to EMBASE, with the same strings, to
COCHRANE LIBRARY, to LILACS. All searches were
done from January 1st, 1998 up to January 31st, 2018.
We have considered papers published in English,
French, German and Italian. Secondary searching was
performed using the bibliography of the most relevant
articles (following PRISMA statement, 2009). Congress
abstracts and isolated case reports were not considered.
We searched the reference lists of articles identified by this
Dovepress Caruso et al
Vascular Health and Risk Management 2019:15 submit your manuscript | www.dovepress.com
DovePress
261
 
Va
sc
ul
ar
 H
ea
lth
 a
nd
 R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
43
.1
60
.3
7 
on
 0
8-
Au
g-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
search strategy and selected those we judged relevantly.
Review articles and book chapters are cited to provide
with additional details.
A total of 560 studies showed up, and appropriate
studies (n=306) were included. The authors carefully
read all the eligible articles (Figure 1).
Cerebral small vessel disease and
blood pressure management
Collecting evidence suggests associations between tradi-
tional vascular risk factors, such as hypertension, diabetes,
hypercholesterolemia, atherosclerosis, cardiovascular and
cerebrovascular involvement, and cognitive disorders and
dementia. These associations are complex and sometimes
differ depending on when in life the risk factors are assessed.
Diabetes is a well-established risk factor for cognitive
impairment, the mechanism of this process, however, is not
fully understand. The effect of insulin acting directly on the
brain is thought to increase the deposition and reduce the
degradation of amyloid-ᵦprotein.49 Interestingly, Okereke et
al showed that women without clinical diabetes but with
higher levels of C-peptide, representing insulin secretion,
had increased risk of cognitive impairment.50 Furthermore,
Luchsinger et al showed that individuals with higher levels of
fasting insulin, with or without clinical diabetes, exhibited a
70% higher risk of developing AD.51
Hypertension has historically been considered as one of
the most critical risk factors for vascular dementia
development,52–54 as one of the many causative co-factor
for neurodegenerative dementia,55–58 and for white matter
lesions.59 Chronic hypertension has been shown to accelerate
amyloid deposition, blood-brain barrier (BBB) dysfunction,
microglial cells activation, and subsequent neuronal loss and
cognitive impairment in animal models.60
Rouch et al reported that patients showing a conversion
from mild cognitive impairment to dementia were signifi-
cantly older, more likely to have hypertension and cardiovas-
cular diseases (Myocardial infarctions, including acute and
subacute myocardial infarctions as well as older ischemic
myocardial lesions). Moreover, long-standing hypertension
is involved in the arterial aging process and arterial stiffness
(also involved in the degenerative process).
Hypertension is a common risk factor for cerebral bleeding
and hemorrhagic stroke, and it has been widely reported that
there is a strict relationship between worse cognitive function
and brain hemorrhage. For example, patients with
Subarachnoid hemorrhage, who have no grossly evident neu-
rological deficits after bleeding, frequently have subtle
435 included
400 included
435 works
400 works
560 articles retrieved from database
265 included and finally examined 95 excluded as pharmacological trials
35 excluded even if concerning specifically SVAD,being isolate
reports or studies including less than 20 participants
125 articles excluded for generic reference of vascular dementia 
(any difference between SVD,multi-infarct etc)
Figure 1 Flowchart of search strategy and selection criteria.
Abbreviations: SVAD, subcortical vascular dementia; SVD, small vessel disease.
Caruso et al Dovepress
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cognitive or neurobehavioral difficulties that impair their
social adjustment and ability to return to their previous
occupations.
On the other side, several epidemiological studies have
also described low blood pressure, especially in later life as a
risk factor for the development of AD, pointing to the poten-
tial risk of over treating hypertension. Indeed, the impact of
hypertension on VAD has been debated and explained by
several mechanisms, centering white matter damages.61,62 It
has also been found that hypertension is equally distributed in
non-lacunar and lacunar lesions and that many patients with
lacunar stroke are normotensive.63 Thus it remains to clarify
whether hypertension alone affects cognitive function or if it
is the effect of higher blood pressure on the cardiovascular
system that is the cause.
The Bronx Aging Study,64 followed an elderly non-
demented cohort (75 years old), for up to 21 years.
Dementia was diagnosed following detailed neuropsycho-
logical testing, clinical examination, and neuroimaging.
Over a median follow-up of 6.7 years, 122 subjects devel-
oped dementia, of these 65 had AD. Participants with
diastolic blood pressure (DBP) of <70 mmHg were twice
as likely to develop AD when compared to those with a
DBP >90 mmHg. The risk was higher in individuals with a
persistently low diastolic blood pressure.
Low blood pressure was described as a predictor of
increased mortality in a 5-year prospective study in Finland
Zhu et al,65 found a significant correlation between low systolic
blood pressure and dementia and hypothesized that hypoten-
sion could be interpreted as a precocious sign of cognitive
decline. This finding was confirmed by Ruitenberg et al,66
who found that low blood pressure is related to a higher risk
of developing dementia, regardless of sex or dementia-type
(both AD and vascular). The risk was more evident in subjects
who were permitted to continue antihypertensive drugs, sug-
gesting that these patients become more prone to hemody-
namic changes, with a higher incidence of watershed
infarcts.66 Burke and colleagues firstly suggested that AD
patients suffered due to pressure dysregulation, caused by
cholinergic impairment.67 Guo et al,68 reported an association
between increased dementia incidence and a relatively low
systolic pressure, associated to a reduction of cerebral flow
(CBF). The reduced CBF might be related to changes in
cerebral vascular autoregulation due to the superimposing
vessel degeneration, the same analysis was also reported
elsewhere.69–71
Nilsson et al,72 reported that in subjects aged 80 or
older, higher systolic blood pressure was associated with a
better cognitive function and a lower systolic blood pres-
sure was associated with cognitive decline and dementia.
Also, many other studies reported a possible effect of low
blood pressure on the cognitive decline.73–75 Guidelines
published by the American Society of Hypertension and
the International Society of Hypertension in 2014,76 sug-
gest a blood pressure <140/90 mmHg for patients younger
than 80 years old, the European Society has suggested a
similar target for Hypertension (ESH) and by the European
Society of Cardiology (ESC).77 The Guideline by the
Eighth Joint National Committee (JNC8) endorses a rea-
sonable target (<150/90 mmHg) in patients aged 80 years
old.78
It appears that white matter alterations are exacerbated
by a significant decrease in blood pressure.79–87 The most
recently published work certified that “midlife not late-life
exposure to the vascular risk factors is important for the
development of dementia”.88,89
Vascular aging is associated with changes in the
mechanical and structural properties of vessel walls,
which leads to the loss of arterial elasticity reducing arter-
ial compliance.90 This induces an alteration in autoregula-
tory capabilities of cerebral arteries, responsible of
cerebral perfusion at a constant rate of blood pressure
(BP). In this situation, the brain may be more vulnerable
to ischemic insults when systemic blood pressure dips
below a critical threshold for maintaining perfusion.91
Orthostatic hypotension is arbitrarily defined as a fall in
systolic BP of 20 mmHg, or a fall in DBP of 10 mmHg on
standing, but when associated with symptoms suggestive
of cerebral hypoperfusion, an even smaller drop in BP may
be of equal importance.92
Several studies have shown an association between
severe cognitive impairment and dysregulation of postural
blood pressure.93 Sudden postural hypotension can cause
relatively prolonged changes in brain perfusion and may
contribute to cause small lacunar events or contribute to
white matter alterations and leukoaraiosis.94,95 Two recent
studies found that orthostatic hypotension was more fre-
quent in AD, with white matter disease than in AD without
white matter disease.96,97 It has been speculated that a lack
of capacity to regulate abnormal blood pressure, well
recognized in AD, leads to chronic dysfunction of cerebral
perfusion and leaves room for the development of white
matter disease.98
Bytheway, in the end, some studies imply that there is a
connection between cognitive impairment and hyperten-
sion, whereas others claim the opposite.
Dovepress Caruso et al
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Considering other risk factors for dementia, the recent
SPRINT-MIND study showed that higher urine albumin
concentration was independently associated with worse
cognitive functioning, including global cognitive function,
executive function, and attention; lower estimated glomer-
ular filtration rate was independently associated with
worse global function and memory, assessing that there
is a strict association between chronic kidney disease and
poorer cognitive function. In the same paper is remarked
that the conversion of patients with mild cognitive impair-
ment to AD is lower in those with well-controlled and
lower blood pressure.99
Pathological aspects of vascular
cognitive impairment: the most
updated vision
A review of pathologic studies shows enormous differ-
ences in the prevalence of VaD ranging from 0.03 to
85.2% with means around 11%, while in recent autopsy
series from Japanese geriatric hospitals it was 23.6 to 35%.
Around Europe, prevalence rates of VaD between ages 65–
69 to 80+ years ranged from 2.2 to 16.3%.10
Fisher was the pioneer in describing the neuropatholo-
gical details in small vessel disease. From autopsy studies,
he observed that majority of the lacunes were due to
segmental arterial disorganization with asymmetrical
focal vascular changes leading at the loss of standard
architecture of the vessels, all these lesions particularly
favor the development of spontaneous hemorrhage, espe-
cially in the deeper areas of the brain.100
The vessel disorders that are most frequently associated
with VaD are atherosclerosis of cerebral arteries (AS), arter-
iosclerosis or cerebral small vessel disease (SVD), and cere-
bral amyloid angiopathy (CAA).101–104 These vessel
disorders frequently occur in the brains of elderly individuals
and become more prevalent and severe with advancing age.
There are less common forms of cerebrovascular disease and
cognitive impairment, including various types of vasculitis
and inherited diseases that affect vessel integrity.
SVD can result in lacunar infarcts, microinfarcts,
hemorrhages, and microbleeds.
In autopsy series of elderly subjects with and without
dementia, the prevalence of “pure” VaD (without conco-
mitant cerebral pathologies) ranged from 5 to 78%, in the
oldest-old from 4.5 to 46.8%.105 The majority of patients
showed Alzheimer-related pathology, only part of them
with AD alone, while mixed pathologies, ie, AD plus
cerebrovascular or Lewy pathology, were seen in 74–
93% and 9–28%, respectively. In the age group 70 to
90+, the prevalence of VaD increased from 13 to 44.8%,
compared to AD (23.6–57%) and mixed dementia (2–
86%). In a consecutive autopsy series of 1700 elderly
demented, the AD without joint pathologies or minor
CVLs, and mixed dementia increased with age. The pre-
valence of “pure” VaD decreased after age >80.
One of the most common causes of these striking
disparities is based on the different pathological features
employed in clinical classifications.106–108
Jellinger et al pointed out various clinical, pathological,
and operative definitions of VaD.10
The simplest include three significant forms: multi-
infarct dementia, single strategic infarct dementia, and
subcortical vascular encephalopathy.
Jellinger suggested a different classification of VaD,
according to primary morphologic lesions, dividing it in
two broad groups: multifocal/diffuse disease (which com-
prises: large vessel dementia; small vessel dementia, dis-
tinguishing the subcortical infarct dementia and the
cortical plus subcortical infarct dementia; hypoperfusion
or hypoxic-ischemic dementia; venous infarct dementia;
and hemorrhagic dementia) and focal vascular disease or
strategic infarct dementia.11
Because this review is focused on small vessel disease-
related dementia, also called sVaD, it is essential to
describe what is known about its underlying pathological
mechanisms. When discussing the microcirculation, we
refer to small arteries and arterioles in the pial and lepto-
meningeal circulation along with penetrating and parench-
ymal arteries and arterioles, pericytes, capillaries, and
venules.
A semantic revision of small vessel
disease
There are estimated to be approximately 47.5 million
people in the world living with dementia, in up to 45%
of whom SVD is a major contributing or the sole
pathology.109 Markers of cerebral small vessel disease
(SVD) are present on neuroimaging of almost all patients
over 60. Small vessel diseases are a group of disorders
that result from pathological alteration of the small blood
vessels in the brain, including the small arteries, capil-
laries, and veins.
Cerebral small vessel disease includes a neuroimaging
description which comprises different imaging changes in
Caruso et al Dovepress
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the white matter and subcortical grey matter, including
small subcortical infarct, lacunes, white matter hyperinten-
sities (WMHs), prominent perivascular spaces (PVS), cer-
ebral microbleeds (CMBs) and atrophy. MRI studies have
questioned the enlarged perivascular spaces (PVS), also
known as Virchow-Robin spaces, as a hallmark feature of
SVD. In healthy tissue, these spaces are proposed to form
part of a complex brain fluid drainage system which sup-
ports interstitial fluid exchange and may also facilitate the
clearance of waste products from the brain. The pathophy-
siological role of PVS, their function and interaction with
cerebral microcirculation, has not been established yet. A
possible mechanism involving impaired cerebrovascular
reactivity (CVR), blood-brain barrier (BBB) dysfunction,
perivascular inflammation, leading to accumulation of tox-
ins, hypoxia and tissue damage, has been questioned.110
There is a broad consensus that PVS form a network of
spaces around cerebral microvessels acting as a canal for
fluid transport, the exchange between cerebrospinal fluid
(CSF) and interstitial fluid (ISF) and clearance of
unwanted products from the brain. In human and animal
model has been proposed a brain lymphatic-like system
called “para-arteriolar,” “para-venular,” “paravascular” or
‘glymphatic. Alteration of this system may induce danger-
ous modification of brain function because undesirable
metabolic products would not be exported and nutrition
would be missed. This complex brain fluid and waste
clearance system appears to be necessary for the clearance
of interstitial solutes from the brain and is most likely vital
for maintaining brain homeostasis.111,112
Enlarged perivascular spaces (EPVS) have been related
to aging, vascular risk factors (VRF) as hypertension, and
other pathological conditions as cerebral small vessel dis-
ease and Alzheimer’s disease.
Has been reported that widening of PVS may indi-
cate obstruction by protein and cell debris and thus
stagnation of fluid drainage, those mechanisms can sup-
port PVS’s role in different diseases, for example
increasing stroke risk particularly with lacunar rather
than large vessel stroke, small vessel diseases and
white matter involvement.113
The role of imaging markers of cerebral small vessel
disease is essential. Cerebral white matter hyperintensities
represent an essential indicator of a higher risk of all-
dementia. Moreover, covert brain infarcts and cerebral
microbleeds are potential risk indicators for incident
dementia in the general population.
The definitions and terms of these
lesions have significantly varied
among studies
As stated by Roman et al,27 the term employed to define
pathological features of the white matter as Binswanger’s
Disease is somehow misleading.
The combination of multiple small deep infarcts and
extensive white matter abnormalities has been referred to as
Binswanger disease, also known as subcortical atherosclero-
tic encephalopathy, and the clinical findings are often classi-
fied as vascular dementia of the small artery type.
White matter hyperintensities are usually symmetrically
and bilaterally distributed in the white matter including the
pons and brainstem, and also occur in deep grey matter. They
appear hyperintense to the healthy brain on T2 or FLAIR
MRI and can be confluent. The pathology of white matter
damage is still imprecise. Mainly it seems due to demyelina-
tion, loss of oligodendrocytes and axonal damage.
Other characteristics aspects are the “lacunes,” term
employed by Fisher to describe a small fluid cavity in
the brain, are very common and usually due to the
micro-infarcts and the micro-bleeds, that are mainly
located in the white matter, especially in the internal
capsule and cerebellar white matter. They can also affect
grey nuclei and deep white matter, such as the basal gang-
lia, thalamus, and brainstem white matter.
Initially, the term lacuna has been employed as a syno-
nym for lacunar strokes, for silent brain infarct and to refer
to the CSF-filled cavities on brain MRI or residual lesion
of a small hemorrhage.114–119 Nowadays, it should be
more appropriate the definition “lacuna of presumed vas-
cular origin“ to replace the term“ lacuna,“ and it should be
avoided the term ”lacunar infarct” to describe the ”lacuna”
by definition. Lacunar infarcts are infarction areas, no
larger than 15 mm; less frequently, they correspond to
small hemorrhagic lesions in a reabsorption phase.120–123
Lacunes and white matter alteration share two common
findings: the same pathogenic start point, arteriosclerosis,
and brain damage vulnus, mainly a previous history of
hypertension. Lacunes, mainly due to complete occlusion
of the small arteries, lead to an infarct in a specific area
(basal ganglia, capsule, pons, etc).
Moreover, there is substantial evidence in SVD of an
associated hypoperfusive course, due to the altered caliber
of small arteries and this is associated with incomplete
ischemia of the deep white matter,124–127 accompanied
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by inflammation, diffuse rarefaction of myelin sheaths,
axonal disruption, and astrocyte gliosis.
In small vessel disease, occlusion of deep periventricular-
draining veins is also evident,128 and it has been described as
a disruption of the blood-brain barrier. This leads a conse-
quent leakage of fluid and plasma cells, which eventually
might potentiate the perivascular inflammation, the demyeli-
nation process, and gliosis, accomplishing a multifactorial
genesis for white matter alterations.129–131
Usually, acute small subcortical infarcts cause specific
neurological symptoms, whereas cerebral small vessel disease
lesions are more insidious, and referred to as silent lesions.116
Finally, concerning neuroimaging findings, cerebral
microbleeds, small round and homogeneous foci of
hypointensity on T2-weighted (gradient echo) MRI and
susceptibility-weighted imaging have been widely
described. Lipofibrohyalinosis and amyloid angiopathy
are the most common vascular findings with cerebral
microbleeds. Distribution of CMB are different concerning
the extension of the SVD pathology, CMBs can be found
in the basal ganglia, thalamus, brainstem, and cerebellum;
they are related to lipofibrohyalinosis, whereas amyloid
angiopathy is more frequently associated with lobar
CMBs. CMBs also contribute to cognitive impairment
and dementia, and neurological deficits. Several studies
showed a significant relationship between CMBs and Aβ
accumulation. Lobar CMBs but not deep CMBs (related to
SVD) was proved to be correlated with Aβ pathology.
The burden of lacunes and deep white matter altera-
tions (WMLs) relates to the degree of cognitive impair-
ment, mainly when they affect the thalamus and basal
ganglia.132–134 The cognitive alterations are determined
by the specific point-to-point impairment, but also by the
interruptions of the cortico-thalamus and thalamus-cortical
networks,135,136 which can also lead to cortical atrophy,
secondary to functional deafferentation.
We agree with Shi and Wardlaw,116 who have written:
common small vessel pathologies and blood-brain barrier
impairment were found in clinically evident and covert
cerebral small vessel disease features, suggesting that it
should be regarded as a whole brain disease rather than
treated separately as an individual condition.
Dynamic process for small vessel
disease
Cerebral small vessel disease is a progressive disease. Lesions
progress over time, and the long-term outcome and impact on
brain damage vary. As far as lesions progress, cerebral small
vessel disease has an uncertain long-term outcome, with a
positive impact on cognition and behavior. Recent studies
indicated that the strongest predictor of white matter progres-
sion is the high baseline white matter hyperintensity, with the
rapid and confluent progression of lesions.137–140 Different
conditions were hereafter considered.
Aging brain and vessel modifying condition
The aging of the brain is due to pathophysiological
changes throughout the single lifetime.
Aging is related to vasculature changes including arterio-
losclerosis and large artery stiffening, which is much more
evident in proximal elastic arteries.141,142 The arterial stiffness
diminishes the so-calledWindkessel effect.143 Windkessel is a
German term, which means air chamber, but it suggests the
elastic reservoir property of vessel.144 Thewalls of all the large
arteries which contains muscle fibers and elastin distend dur-
ing systole and recoil during diastole. Since the amount of
blood entering during the systolic time is larger than the de-
flux of it in diastolic time, caused by peripheral resistance, the
large arteries behave themselves as a capacitor. The
Windkessel effects help in damping the fluctuation of blood
pressure over the cardiac cycle. The Windkessel model is
accompanied by the more recent theory of arterial accelera-
tion. The onset of systole triggers a short lasting depolarization
within smoothmuscle cells, that spreads along the arterial tree,
as a peristaltic wave; this could happen in order to amplify and
distribute the pressure wave, over the arterial branches, allow-
ing to penetrate the most profound regions.145
The most determinant effect result is an anticipated
and precocious return of the so-called wave reflection,
an increase of systolic and the decrease of diastolic
pressure [144]. The brain usually has a high resting
flow which seems to be related to the fact that heart
pulsation (plus the Windkessel effect) produces a higher
perfusion pressure toward the most profound small
arteries of the brain.146,147
Hypertension promotes the underlying age-related
mechanism of arteriolosclerosis, promoting micro-athero-
matosis, which can rapidly lead to stenosis, or different
degrees of vessel occlusion until the complete lumen
occlusion, inducing ischemia and brain damage.148
Besides the potential effect on arterial arteriosclero-
sis, a fundamental role is played by subsequent hemo-
dynamic alteration that may lead to a diminishment of
blood perfusion in the brain.149,150
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Like in a magic circle, the hypoperfusion, the arterio-
losclerosis damage and the altered reflection on cerebral
blood flow velocity perpetuates the arterial stiffness.
Aging also interferes with the brain autoregulation prop-
erty. Cerebral vasoregulation is a dynamic process that redis-
tributes cerebral blood flow (CBF) toward the brain areas in
need of increased perfusion. Vasoreactivity reflects the abil-
ity of microvasculature to adapt to a changing environment,
which causes fluctuatingmetabolic demands (such as oxygen
and glucose delivery and blood pressure variations). As we
already reported, chronic hypertension and hypotension alter
CBF autoregulation and may affect the autoregulatory range.
“Autoregulation” most commonly refers to CBF adap-
tation to acute and chronic changes in arterial BP and
perfusion pressure. Pressure autoregulation maintains
fairly-stable perfusion over the range of mean systemic
pressures 60–150 mmHg.151–153
Age-related endothelial dysfunction and risk factors
such as hypertension and DM set the stage for altered
neurovascular coupling and a regional decline in vasomo-
tor capacity; all those factors reshape the sigmoidal phy-
siologic curve of the adaptive system into “a straight
line.”144
There is a strong association between hemodynamic
and structural alterations of the cerebral arteries and cog-
nitive impairment, suggesting that decreased cerebral
blood flow, diffuse brain microvascular disease, increased
arterial rigidity (resulting in decreased arterial compliance
and putative myocardial impairment) are functionally
linked to dementia. Several studies, based on transcranial
Doppler ultrasounds examination of CBF, have reported
lower mean flow velocity and decreased cerebrovascular
reactivity in the middle cerebral artery in demented
patients compared to controls.154–157
Moreover, it has been documented marked cholinergic
denervation of small arteries in the brain.158The lack of
muscarinic cholinergic receptors in the penetrating vessels
might lead to a vital blood flow dysregulation, with scare
response to blood pressure modifications and have as a
consequence a loss of efficacy in vasomotor coupling
response.159–161
Finally, the aging effect involves also oxidative stress
at an early stage. The reactive oxygen species (ROS)
produced during mitochondrial oxidative phosphorylation
are associated with damage to DNA, lipids, and proteins.
The accumulation of mitochondrial DNA mutations
induces impairment of mitochondrial function. Mutations
in mitochondrial DNA and oxidative stress both contribute
to neuronal aging and neurodegeneration.162,163 All those
changes contribute to neuronal loss. The effect of aging
does not occur to the same extent in all brain regions. For
example, compared to cerebral areas, the cerebellum is
protected from aging effects. Usually, the prefrontal cortex
is most affected and the occipital least. Frontal and tem-
poral lobes are most affected in men compared with the
hippocampus and parietal lobes in women.164
Metabolic and regional vulnerability
Petito et al,165 reported that after 10 mins of transient global
ischemia in the rat brain, the initial changes occur in peri-
neuronal spaces and subcortical white matter, preceding neu-
ronal death by several days.166 The authors demonstrated the
selective death of the gray matter oligodendrocytes one day
after ischemia, suggesting that oligodendroglia might be
more neurons in the cerebral cortex and thalamus, the
damage is absent or minimal. These results appear concor-
dant with other in vitro findings.167,168 Moreover, oligoden-
droglia cell death precedes neural necrosis after focal
ischemia. Furukawa et al,169 described the time course of
microglial activation after ischemia, with regional variability,
probably due to differential selectivity across brain regions,
just as what described by Gehrman et al170. They observed
that the most significant and precocious microglial activation
occurs in the hippocampus, soon after ischemia induction,
and this decreases after 48 h. Afterward, microglial activa-
tion is slowly evident in the white matter and cortex, with an
increasing trend, mostly at 48–72 h after ischemia induction.
Rupalla et al,171 found that in adult mice, microglial activa-
tion increased from days 2 to 30 and days 2 to 4 after
ischemia in the thalamus and cortex, respectively.
Furukawa et al,169 hypothesized two subsets of microglia
activation: Ml activation that induces the formation of oxi-
dative metabolites, proteases, and cytokines after ischemia,
and M2 activation that antagonizes inflammation.172 The
authors demonstrated that the extent of white matter damage
might be associated with more extensive activation of Ml
microglia, implying that blocking this process could reduce
brain damage,173 (following Yuan et al161).
Chronic cerebral hypoperfusion has been proposed as
vascular risk factors for white matter injury.174 Different
experimental models which studied the hypoperfusion of
the corpus callosum with a stabilized drop of 52–64% of
the original flow at 30 days after the ligation.175 The
following white matter alteration revealed axonal damage
and diffuse demyelination, indicated by an increased amy-
loid precursor protein expression and encephalitogenic
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peptide elevation.176 Oligodendrocyte degeneration was
due to apoptotic cell death, with caspase 3 RNA detection,
associated to an elevation of matrix- metalloprotease 2
(MMP-2) expression and microglial activation.177 More
recent data confirmed that glial changes in chronic cerebral
hypoperfusion could induce white matter damage, region-
specific mild astrogliosis, marked microglial activation
and increased oligodendrocyte density and diffuse myelin
damage.178 It has been demonstrated that astrocytes react
to ischemia concerning the length and severity of the
insult. In the early ischemic period, the astrocytes respond
with proliferation and, following persistent hypoperfusion,
with degeneration and death.179 Interestingly, in the white
matter and the frontal cortex of demented patients, the
disintegration and the regression of astrocytes has been
demonstrated and related to ischemia.180,181
When the CBF is not stopped, but it is reduced or not
well matched to the energy demands of the tissue, chronic
brain injuries occur in different areas, standing on a dif-
ferent degree of vulnerability,182 As we documented
before, the neurocentric vision of the brain is no longer
supported. It is quite clear that the normal functions of the
brain depend on functional interactions among different
components in the neurovascular unit, which includes
neurons, oligodendrocytes, microglia, and astrocytes and
vascular cells (endothelial cells, pericytes, and smooth
muscle cells) and the basal lamina matrix within brain
vasculature.183 Therefore, possibly through glutamate
signaling,184 astrocytes respond to the metabolic changes
of neurons. Astrocytes monitor neuronal activity and con-
tribute to the regulation of blood flow modifying capillary
permeability, by stretching out their endfeet to the micro-
vessel and establishing a proximal connection with the
capillary. The combined effect might lead to instant reg-
ulation of CBF according to neuronal activity, in the so-
called neurovascular coupling.185
Moreover, endothelial cells are receiving growing
interest. As pointed out by Iadecola,186 in the resting
brain, CBF varies in proportion to the energy consumption
of each brain region. Each increase in neuronal activity
leads to increases in CBF in the activated areas, permitting
a flow response to map brain functions,187 The evidence is
increasing on pial arterioles: signals generated by the
neuronal activity, deep in the brain, have to be conveyed
to upstream arterioles, remote from the area of activation,
to increase flow efficiently. Vascular mapping and fMRI
demonstrated that during somatosensory activation vascu-
lar responses are first seen in the deep cortical lamina, and
then, more superficially, suggesting a retrograde propaga-
tion of the vascular response.188 A possible scenario for
the transmission and coordination of the vascular response
is described by Iadecola,186 as follows: activation-induced
increases in extracellular potassium triggers hyperpolariza-
tion of capillary endothelial cells and pericytes.189
The hyperpolarization propagates upstream and
reaches smooth muscle cells in penetrating arterioles pro-
ducing relaxation. At the same time, metabolic modifica-
tions (reduced viscosity, increased deformability of blood
cells) on the endothelium of feeding arterioles increment
the smooth muscle cell relaxation (the so-called flow-
mediated vasodilation). In upstream pial arterioles remote
from the site of activation, there is vasodilation, by pro-
pagation from arteriole downstream and acting as a local
flow-mediated and myogenic response.
Moreover, there are also regional differences in the
basal regional metabolic response.
A recent in vivo-study,190 confirmed that the caudate
nucleus most precociously affected brain region, followed
by the putamen, insula, precentral gyrus, inferior frontal
gyrus, and middle frontal gyrus, which requires, at steady
state than 20% of the metabolic request, then other brain
regions.191–197
Non-demented patients with lacunar infarcts do not
show cerebral flow alterations in grey matter, but they
exhibit a decrease of more than 30% in white matter, asso-
ciated with increased oxygen extraction of more than 130%
in comparison with healthy subjects. On the contrary,
patients with lacunar events and cognitive impairment
have a reduced metabolic rate for oxygen, about 25% and
35% lower in grey and white matter, respectively.198,199 As
a conclusion, an incongruity between the brain oxygen
supply and its consumption has been described due to
small vessel disease; this altered ratio causes an impaired
neurovascular coupling and determines an altered vasomo-
tor reactivity.200–205 Tak et al,200 by employing spectro-
scopy confirmed a reduced blood flow and low extraction
of metabolic oxygen in the frontal lobes, during the resting
state in subjects with small vessel disease. These changes
have been observed not only in subcortical, profound
regions,200–202 but also in frontal cortical areas. This was
unexpected, and not fully understood, apart from the appar-
ent speculation that cortical damage may be related to
axonal dying back or Wallerian degeneration.206
Another novel aspect of the work by Tak et al,200 is the
finding that in small vessel disease, the fractional change of
oxygen extraction is increased during activation tasks
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(lower than average, in resting state). However, the oxygen
extraction is not sufficient to guarantee a proper activity, due
to the decrease of blood flow (mainly due to smooth muscle
alterations and arterial stiffness) and to the pre-existent low
metabolic oxygen rate. The temporary augmentation of
oxygen extraction implies a further loss of the metabolic
reserve,207 leaving the brain tissue more vulnerable to
hemodynamic changes. Moreover, the clinical severity of
white matter pathology is inversely related to glucose meta-
bolism in the dorsolateral frontal lobe. Chui explained this
finding with the hypothesis that the long neural fibers that
connect the prefrontal-cortical areas to the periventricular
brain regions are dependent on small, terminal arteries that
are affected by arteriosclerosis.208
Cholinergic dysregulation in small vessel
disease
A cholinergic deficit in the brain and cerebrospinal fluid of
patients with vascular dementia has been widely reported.
Also, cholinergic therapies have shown promising effects
on cognitive improvement in those patients, even if its
precise mechanisms are not well-known jet.209,210
Wilkinson et al,211 reported that patients with VAD
treated with Donepezil (an acetylcholinesterase inhibitor)
showed benefits in cognition and global function com-
pared to placebo. Moreover, a significant improvement of
dementia severity and slowed functional deterioration was
seen.
The safety profile of donepezil has been reported in
possible and probable VAD and AD; donepezil may be
well tolerated, even in a relatively frail population of
elderly patients with considerable comorbidities.212
Albeit, its role in VaD treatment is still debated. O’Brien
and Thomas in 2015 suggested that cholinesterase inhibi-
tors and memantine should not be used in patients with
vascular dementia. Actually, in a different randomized
controlled trial, a small but significant benefit of cholines-
terase inhibitors on cognition was seen in vascular demen-
tia, but the benefits on global functioning, activities of
daily living, and behavior have not been consistently
reported. Finally, the possible side-effects of those drugs
must be taken into account.213,214
Data suggest that the cholinergic system and cerebral
blood flow are linked reciprocally. An anti-inflammatory
pathway in which the efferent vagus nerve signals sup-
press pro-inflammatory cytokine release and inhibit
inflammation has been questioned.
The concept of the “cholinergic anti-inflammation
pathway” has been first proposed by Tracey et al; these
findings are based on the knowledge that acetylcholine
(Ach) released from cholinergic axon terminals can inter-
act with α7 nicotinic Ach receptors (nAChRs) on vicinal
immune cells.215,216 The nicotinic receptors then translate
the cholinergic signal into the suppression of cytokine
release, involved in the inflammatory cascade.217,218
Cholinergic agents include ACh precursors, which
increase the synthesis of ACh; nicotinic or M1 muscarinic
agonists, which directly stimulate cholinergic receptors or
allosterically modulate AChR,219 and synaptic AChE inhi-
bitors, which prevent the degradation of ACh.
Data from literature showed that both in animal models
and postmortem studies there is reduced CSF ACh con-
centrations in patients with Binswanger or multi-infarct
dementia.220,221 Animal models of sVaD (stroke-prone
rats) show significant reductions in ACh levels in the
cortex, hippocampus, and cerebrospinal fluid.222–225
Furukawa et al,226 investigated the role of ACh in the
development of hypoxia-ischemia lesions using in vivo
animal models. They demonstrated that muscarinic recep-
tor antagonism with atropine has a selective effect of
worsening the ischemic damage, but only in the CA1
region. Selective alpha-7- nicotinic AChR antagonists
exacerbate changes in the cortex and CAl and CA3
areas, while non-selective nicotinic AChR antagonists
have a detrimental effect on the hippocampus but not in
all the cortical areas examined.227 It is accepted that AChR
stimulation reduces hypoxic-ischemic brain damage in rat
pups and reduces the cytokine production as a conse-
quence of hypoxia-ischemia damage.228–230
Elsewhere a loss of cholinergic neurons in 40% of VaD
patients was reported, accompanied by reduced ACh activ-
ity in the cortex, hippocampus, and striatum.231
Changes in cerebral blood flow can affect control choli-
nergic networks, and a proper cholinergic function is man-
datory to regulate regional brain blood flow.232,233 In
primates, the central cholinergic system has three main com-
ponents: the projections from the basal forebrain, innervating
the hippocampus, cortical regions, and some subcortical
nuclei; the projections from the brainstem which innervate
the thalamus and the midbrain, as well as the brainstem;
finally, the striatal and accumbens interneurons.234,235
The forebrain cholinergic bundle is supplying both the
medial and lateral pathways loops around the anterior cor-
pus callosum and the frontal horns of the ventricles. It is
well-accepted the parasympathetic innervation of the circle
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of Willis, and pial vessels are principally mediated by
Ach.236 Ach produces significant in vitro arterial relaxation
per se and by increasing the synthesis of vasodilator
endothelium agents, via the nitric oxide synthase,237 and
via the GABA interneurons.238–240
The stimulation of the Nucleus Basalis of Meynert
results in increased blood flow throughout the cerebral
cortex in experimental animals.241 On stimulation, peri-
vascular cortical afferents release Ach into endothelial M5
muscarinic receptor.242,243 M5 receptors are highly
expressed in blood vessel walls. Yamada et al,222 prepared
knockout mice (M5-/-) and found that compared to wild-
type mice, these animals lose the ability to dilate cerebral
arteries but could still regulate extra-cerebral flow; it has
been suggested that the neural network from the Meynert
nucleus may influence the small arteries also indirectly.
Age-related impairment of vascular autoregulation is
also due to a low-level functioning of the autonomic
nervous system, with direct and endothelium-mediated
altered baroreflex activity.244–246
Small vessel disease, due to the primary localization
of the white matter hyperintensities, may affect the
integrity of the adjacent medial cholinergic pathway.247
Post-mortem studies in CADASIL demonstrated that
cortical cholinergic projections from the Meynert could
be affected as a consequence of white matter lesions.
Bohnen et al,247 demonstrated in vivo that the severity
of the periventricular white matter lesions is associated
with lower AchE activity, in the middle-aged and
elderly subjects without dementia, as a result of cortical
cholinergic deafferentation.
Post-mortem sVaD studies revealed lower choline acet-
yltransferase (ChAT) activity compared with controls,248
and sVAD patients have lower CSF concentrations of
Ach.223–225,249
There are some clinical data which confirm a reduction
of the number of cholinergic neurons in the Nucleus
Basalis of Meynert in multi-infarct dementia, but not in
sVaD.250–252 Though, the number of muscarinic choliner-
gic receptors is markedly reduced in mixed dementia
patients,253 and in small vessel disease-related dementia.
The cholinergic impairment is not mediated by a primary
loss of the cholinergic neurons of Nucleus Basalis of
Meynert,254,255 but rather it is a consequence of the sec-
ondary cholinergic deficits, due to the indirect less effica-
cious endothelium mediation through the nitric oxide
synthase and the GABA interneurons.237,238 The two med-
iators seem less efficient to influence the small arteries
contraction also due to the significant coexistent altera-
tions of the endothelium.256–259
The pathological cascade of events, which occurs as a
consequence of all the pathological alterations described,
determines a decrease of the vascular tone, with a release
of the blood-brain barrier permeability, with internal vas-
cular remodeling and with vascular rarefactions. As a
result, hypo-perfusion at rest occurs in the brain, combined
with an impairment in the moment-to-moment control of
CBF, associated to a decrease of adaptive vascular
responses and a diminishment of the neurovascular cou-
pling and auto-regulation system.257
More recent studies have suggested an important role
for the autonomic nervous system in the maintenance of
cerebral perfusion.260–262 It has been suggested that choli-
nesterase inhibitors modulate cerebral vascular functions,
due to the possible role of the cholinergic fibers in cerebral
flow regulation.263 Moreover, an active cholinergic vasodi-
latory reflex in the cerebrovascular system has significant
clinical implications for the use of acetylcholinesterase
inhibitors in the potential adjuvant treatment for ischemic
strokes.264 Moreover, the same authors demonstrated that
increasing cholinergic activity might also improve cerebral
perfusion and autoregulation in demented patients.265 Once
more, the distribution of muscarinic receptor subtypes may
play a key role in how vasodilation is affected: in skeletal
muscle, M3 receptors are dominant and are responsible for
the vasodilatory response to acetylcholine.266 On stimula-
tion, perivascular cortical afferents release Ach onto
endothelial M5 muscarinic receptor,267,268 highly expressed
in blood vessel walls.267 Hamner et al,261 in a limited, but
well-conducted study demonstrated in healthy volunteers
that cholinergic control of the cerebral vasculature might be
active at low frequencies, lower than 0.05 Hz when the
sympathetic nervous system appears to play a role in the
cerebral auto-regulation. At these low frequencies, even the
myogenic mechanisms appear to play any role; to surprise,
the correspondence between cholinergic and sympathetic
cerebrovascular regulation above 0.05 Hz is striking, sug-
gesting that the cerebral circulation engages different
mechanisms to protect against rising and falling pressures.
It has been demonstrated that the endothelial cells of
brain arterioles promote and activates the neuronal signal-
ing, the synaptic transmission, oligodendrocyte and white
matter regulation, neurogenesis while inhibiting the acti-
vation of the microglia.269,270
Moreover, the cholinergic impairment for artery dysregu-
lation observed in small vessel disease could also derive from
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the deafferentation of the basal forebrain cholinergic system
to the subcortical structures.271,272 These findings are asso-
ciated with a reduced synaptophysin immunoreactivity.273 In
animal models, a reduction of vasopressin and histamine has
been confirmed as a result of the deafferentation of the neural
tracts from the supra-optic and tuberomammillary nuclei to
the basal forebrain,274 with a possible self- potentiating
reduction of perfusion.
The presence of lacunes and white matter lesions
affecting the deep neural networks located between frontal
cortical areas and basal ganglia/thalamus and anterior cin-
gulate cortex,197,275 may account for secondary cholinergic
basal-forebrain de-afferentation. Neural activity is typi-
cally accompanied by increased blood flow, with vascular
dilatation propagated in a retrograde manner to upstream
arterioles, located outside the activated area.276 The altered
“retrograde vasodilatation system” (which occurs in small
vessel disease-related dementia) could be a possible factor
that may worsen vessel dysregulation.
Small vessel disease: yin and yang in
subcortical vascular dementia
Small vessel disease and white matter abnormalities are
seen frequently with aging.
The most relevant questions are: does the coexistence
of small vessel disease and white matter alterations do
represent a biological variant of healthy aging, or is
small vessel disease the predictor of future dementia?
The answers are ambiguous.226
Animal models and human clinical studies showed that
white matter alterations are associated with cognitive and
behavioral disruptions. Though, as clearly stated by De
Silva and Faraci,:118 “the associations between vascular
disease and cognition are based primarily on the temporal
relationship between these endpoints.”
What is lacking is a solid demonstration of the exis-
tence of a causative determinant, testifying the relation
between subcortical networks disruption (due to small
vessel disease) and the clinical definition of subcortical
vascular dementia.
What emerges from literature are some statements: first
of all, vascular and endothelium changes have been related
with age; the changes can be accelerated by different
vascular risk factors (hypertension, hemodynamic
changes, diabetes227,228); secondly, vascular function
changes can be heavily influenced by genetic and epige-
netic factors,:269 they directly influence the endothelium
resistance. These changes induce a progressive decrease in
CBF which is thought to be one of the key element for the
progression from small vessel disease towards subcortical
vascular dementia.277 Aging is the most important non-
modifiable risk factor for the development of white matter
hyperintensities and their progression towards confluent
white matter damage, for endothelium injuries, for their
progression and the increased blood-brain barrier
permeability.278–280 Moreover, the subcortical vascular
dementia might be characterized by focal, even subtle
neurological signs (such as slight motor hemiparesis, bul-
bar signs, gait imbalance, hypokinesia, etc.281,282).
Another important key point is that the early cognitive
syndrome for subcortical vascular dementia is defined by
a dis-executive syndrome, with decreased abilities in goal
formulation, set-shifting, and execution, associated to
major problems in the retrieval of information.283–286
Similarly, behavior disruption is even more typical, with
marked emotional lability, emotional bluntness, 287 and
apathy.288,289 What has been described as a typical neu-
ropsychological profile of subcortical vascular dementia
can be attributed to damage to the prefrontal-frontal sub-
cortical cortical networks.290–292
Tak et al,200 found significant alterations of the hemo-
dynamic and metabolic responses also in the frontal cor-
tical areas of patients suffering from small vessel disease.
This can be related to axonal dying back or Wallerian
degeneration,206 but it is also supported by a metabolic
imbalance, due to an increased fractional change of oxy-
gen extraction, during activation tasks, not sufficient to
compensate for the constant decrease of CBF and the
low metabolic oxygen rate. The increased oxygen extrac-
tion implies a progressive loss of the metabolic reserve.207
Different studies pointed out that even in the healthy
aging brain, some cognitive, age-related modalities have
been related to frontal lower metabolism.293,294 The ongoing
process or sudden precipitating events may transform the
standard aging-related subcortical alteration in dementia.
The cerebral small vessel disease has been traditionally
distinguished from a neuropsychological perspective from
subcortical vascular dementia.294 Awell-conducted study,295
stated that lacunar infarctions and deep white matter hyper-
intensities seen on MRI did not correlate with neuropsycho-
logical impairments and they should be considered as
“epiphenomena that morphologically characterize cerebral
small vessel disease, but do not, in and themselves, indicate
cognitive impairment.” Nonetheless, different studies indi-
cated that lacunes and white matter hyperintensities were
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associated with dis-executive syndrome,296,297 and when
lacunar events can be thoroughly studied, neuropsychologi-
cal dis-executive functions can be found out in more than
55% of cases, concluding that the process from small vessel
disease to subcortical vascular dementia is ongoing and its
incidence is still under-recognized, in clinical and research
studies.298
These conclusions are in line with those derived by more
consistent studies and even recent studies.299,300 These stu-
dies indicated that most of their participants, affected by
small vessel disease, demonstrated cognitive performances,
below one standard deviation from the normative mean
scores in executive functions. These data suggest therefore
that small vessel disease could be considered as a fore-runner
condition of subcortical dementia, in due time course.
Finally, the pattern progression from small vessel dis-
ease to subcortical dementia has been debated by two
more recent works. Nitkunan et al,301 verified that the
cognitive and executive dys-functions are related to the
brain volume decline, which is progressive with time
course. More sophisticated studies,302,303 suggested that
the progression pattern of brain structural changes in
patients with small vessel disease is consistent with the
topography of selective cortical atrophy (mainly in frontal,
perisylvian and posterior cingulate regions).304–307 The
atrophy extends further towards the parietal and medial
temporal regions, when patients manifested the definite
signs of subcortical vascular dementia, exhibiting addi-
tional atrophy in the lateral head and inferior body of the
hippocampus.
Taken together, all the data as mentioned earlier indi-
cate that patients with small vessel disease manifest cog-
nitive and behavioral impairments. They are consistent
with subcortical frontal networks disruption and their evo-
lution towards subcortical vascular dementia is consistent
with the progression of the cortical thinning of prefrontal,
frontal areas and with an evident shape alteration of the
lateral head and inferior body of the hippocampus. Still
debated aspects are time course, precipitating factors, and
individual variability.308
Conclusions
At the end of this review, there are some solid conclusions
and many points that require further studies. The positive
aspects are:
1. Small vessel disease and the related dementia are
two unambiguous nosographic entities that deserve
attention for their relevance and impact in clinical
practice.
2. Hypertension might be a historical problem of
patients who suffer from small vessel disease and
small vessel disease-related dementia, but at the
diagnosis of small vessel disease, patients are more
vulnerable to brisk pressure lowering
3. CBF regional selective decrease seems to be one of
the critical factors for the progression from small
vessel disease to small vessel disease-related
dementia.
4. The arterioles are the targets of small vessel dis-
ease and sVaD, with degeneration of the smooth
muscle layer, replacement by hyaline fibrosis, lead-
ing to a subtotal luminal occlusion. Patients suffer-
ing from small vessel pathology are therefore more
sensitive to any pressure changes. Endothelium
damage is a super-imposed, not irrelevant,
condition.309
5. Acetylcholine intimately regulates CBF through the
parasympathetic innervation of the circle of Willis
and pial vessels. It causes significant arterial relaxa-
tion by promoting the synthesis of vasodilator
agents; a secondary acetyl- cholinergic impaired
regulation characterizes small vessel disease.
6. These aspects determine the sensitivity of elderly
patients with dementia to hypotension and each
clinical condition that may lead to hypotension
might accelerate underlying degenerative processes.
The most relevant still under debate-aspects are:
1. The modality of changing from normal aging small
vessel disease towards dementia
2. The influence of cells, other than neurons and astro-
cytes, including microglia, oligodendrocytes, peri-
vascular and meningeal macrophages in vessel
control and endothelium degeneration
3. The impact of aging and the age-gene interactions
in lipohyalinosis and endothelium disruption,
caused, promoted or potentiated by hypoperfusion
and metabolic disruption.
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